Recombinant Collagen 7 Formulation for DEB Skin Integrity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dystrophic epidermolysis bullosa (DEB) lack effective solutions to restore skin integrity and manage the chronic blistering and scarring, as existing therapies focus on supportive care rather than addressing the underlying collagen VII deficiency.
Innovation Solution
Compositions comprising recombinant collagen 7, sodium phosphate, sodium citrate, arginine, a sugar, and a surfactant, such as polysorbate 20, are developed to enhance protein stability and solubility, allowing for increased concentration and improved handling and storage, including formulations like 10mM sodium phosphate, 5mM sodium citrate, 100mM arginine, 50mM sucrose, and 0.05% polysorbate 20, which maintain stability and potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If recombinant collagen 7 is prepared in PBS buffer, then the protein can be produced, but it precipitates at higher concentrations due to stickiness
Solution Approach 1:
The patent changes the buffer parameters from PBS to a formulation containing sodium phosphate, sodium citrate, arginine, and polysorbate 20. This parameter change resolves the precipitation issue by modifying the chemical environment to prevent collagen 7 stickiness while maintaining solubility at higher concentrations (up to 10 mg/mL).
Solution Approach 2:
The patent introduces intermediary substances (arginine, polysorbate 20, sodium citrate) that mediate between the collagen 7 protein and the buffer environment. These intermediaries prevent direct protein-protein interactions causing precipitation, allowing higher protein concentrations to remain soluble and stable.
2Reliability
If collagen 7 is stored without stabilizers, then the formulation is simple, but it lacks robustness against freeze-thaw and thermal stresses
Solution Approach 1:
The patent creates a composite formulation by combining collagen 7 with multiple stabilizing components (sodium phosphate, sodium citrate, arginine, sucrose, polysorbate 20). This composite approach provides comprehensive protection against various stresses (freeze-thaw, thermal, agitation) that single stabilizers cannot achieve alone.
Solution Approach 2:
The formulation includes stabilizers that provide beforehand cushioning against anticipated stresses. The arginine and polysorbate 20 prevent aggregation before it occurs during freeze-thaw cycles or thermal stress, while sucrose provides cryoprotection before freezing occurs.
3Reliability
If collagen 7 is administered to treat DEB, then skin integrity can be improved, but the underlying collagen VII deficiency cannot be addressed with supportive care alone
Solution Approach 1:
The recombinant collagen 7 protein serves as a self-replenishing therapy where the administered protein directly replaces the deficient endogenous collagen VII. The protein self-assembles into anchoring fibrils at the basement membrane zone, restoring the structural function without requiring the patient's own defective collagen synthesis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions demonstrate increased stability and solubility, achieving up to ten-fold higher protein concentrations, improved robustness against freeze-thaw and thermal stresses, and effective delivery, with significant improvements in skin integrity and survival in DEB mouse models.
Implementation Method 1
a surfactant, such as polysorbate 20, are developed to enhance protein stability and solubility
Implementation Method 2
the rC7 protein demonstrates 'stickiness,' and the propensity to precipitate at higher protein concentrations, particularly in PBS buffer
Implementation Method 3
sodium phosphate, sodium citrate, sodium chloride, arginine, a sugar, and a surfactant
Implementation Method 4
improved robustness against freeze-thaw and thermal stresses
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
The present disclosure relates to compositions comprising collagen 7 and methods of using the same to treat DEB.